Nov 6 (Reuters) - Viralytics Ltd VLA.AX :
* Viralytics and Merck (N:MRK) collaborate in lung and bladder cancer VLA.AX
* Entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co.,
* Deal to evaluate the combination of viralytics' investigational cancer immunotherapy cavataktm, with msd's keytruda
* Says Viralytics, in collaboration with msd, will be the sponsor of the study, which is planned to begin in 2016
* Says agreement includes a provision where the parties may extend the collaboration to include a potential phase 3 clinical trial
* Says additional details of the collaboration were not disclosed
* Source text for Eikon ID:nASXgS4Xs
*